III CONSERVATIVE TREATMENT NEUROLOGIC URINARY INCONTINENCE

tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10.

36. Chapple CR, Cardozo L, Steers WD and Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006; 60: 959-66. 37. Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J,

Scarpa RM et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007; 52: 1195-203.

38. Cardozo L, Lisec M, Milard R, Van Vierssen Trip O, Kuzmin I, Drogendijk TE et al. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder]. Akush Ginekol (Sofiia) 2007; 46: 55-7.

39. Haab F, Cardozo L, Chapple C and Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84.

40. Foote J, Glavind K, Kralidis G and Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48: 471-7.

41. Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025-32.

42. Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95: 993-1001. 43. Chapple C, DuBeau C, Ebinger U, Rekeda L and Viegas A. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12- week trial. Curr Med Res Opin 2007; 23: 2347-58. 44. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J and

Guan Z. Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome. Urology 2008;

45. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.

46. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag- Molkenteller C, Massow U et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 2488-94.

47. Brendler CB, Radebaugh LC and Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989; 141: 1350-2.

48. George J, Tharion G, Richar J, Macaden AS, Thomas R and Bhattacharji S. The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury. ScientificWorldJournal 2007; 7: 1683-90.

49. Evans RJ. Intravesical therapy for overactive bladder. Curr Urol Rep 2005; 6: 429-33.

50. Lecci A, Giuliani S, Meini S and Maggi CA. Nociceptin and the micturition reflex. Peptides 2000; 21: 1007-21. 51. Lazzeri M, Calo G, Spinelli M, Malaguti S, Guerrini R,

Salvadori S et al. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol 2006; 176: 2098-102.

52. Fader M, Glickman S, Haggar V, Barton R, Brooks R and Malone-Lee J. Intravesical atropine compared to oral

oxybutynin for neurogenic detrusor overactivity: a double- blind, randomized crossover trial. J Urol 2007; 177: 208-13; discussion 213.

53. de Seze M, Gallien P, Denys P, Labat JJ, Serment G, Grise P et al. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study. Neurourol Urodyn 2006; 25: 752-7. 54. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab

F, Everaert K et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200.

55. Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174: 1873-7; discussion 1877. 56. Duthie J, D.J. W, Herbison GP and Wilson D. Botulinum toxin injections for adults wih overactive bladder. The Cochrane library 2007; 1-14.

57. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E and Porena M. Intravesical resiniferatoxin versus botulinum- A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172: 240-3. 58. Karsenty G, Carsenac A, Boy S, Reitz A, Tournebise H,

Bladou F et al. Botulinum toxin- A (BTA) in the treatment of neurogenic detrudor overcativity (NDOI)- A prospective randomized study to compare 30 vs. 10 injection sites. Eur Urol 2007; 2: 245.

59. Thavaseelan JT, Burns-cox N, Jordan K and Trewhella J. Efficacy of botuinum toxin type A (BOTOX) in the management of the neurogenic bladder: a prospective, randomsed, double blind dose comparative trial. BJU Int 2005; 95: 4-5.

60. Truzzi J, Bruschini H and Simonetti R. What is the best dose for intravesical botulinum-A toxin injected in overactive bladder treatment: a prospective randomized preliminary study. Proceedings of he International Continence Society and the Urogynaecological association, 2004; August 23-27, Paris:

61. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007; 41: 335-40.

62. Stankovich E, Borisov VV and Demina TL. [Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis]. Urologiia 2004; 48-51.

63. Abrams P, Amarenco G, Bakke A, Buczynski A, Castro-Diaz D, Harrison S et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170: 1242-51. 64. Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze

M and Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2005; 76: 1670-6.

65. Mehnert U, Boy S, Svensson J, Michels L, Reitz A, Candia V et al. Brain activation in response to bladder filling and simultaneous stimulation of the dorsal clitoral nerve--an fMRI study in healthy women. Neuroimage 2008; 41: 682-9. 66. Wheeler JS, Jr., Walter JS and Zaszczurynski PJ. Bladder

inhibition by penile nerve stimulation in spinal cord injury patients. J Urol 1992; 147: 100-3.

67. Dalmose AL, Rijkhoff NJ, Kirkeby HJ, Nohr M, Sinkjaer T and Djurhuus JC. Conditional stimulation of the dorsal penile/clitoral nerve may increase cystometric capacity in

patients with spinal cord injury. Neurourol Urodyn 2003; 22: 130-7.

68. Hansen J, Media S, Nohr M, Biering-Sorensen F, Sinkjaer T and Rijkhoff NJ. Treatment of neurogenic detrusor overactivity in spinal cord injured patients by conditional electrical stimulation. J Urol 2005; 173: 2035-9.

69. Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J and Van Den Hombergh U. A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn 2005; 24: 305-9.

70. Andrews BJ and Reynard JM. Transcutaneous posterior tibial nerve stimulation for treatment of detrusor hyperreflexia in spinal cord injury. J Urol 2003; 170: 926.

71. Krivoborodov GG, Gekht AB and Korshunova ES. [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease]. Urologiia 2006; 3-6.

72. Baumer T, Lange R, Liepert J, Weiller C, Siebner HR, Rothwell JC et al. Repeated premotor rTMS leads to cumulative plastic changes of motor cortex excitability in humans. Neuroimage 2003; 20: 550-60.

73. Centonze D, Petta F, Versace V, Rossi S, Torelli F, Prosperetti C et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler 2007; 13: 269- 71.

74. Lemack GE, Dewey RB, Jr., Roehrborn CG, O'Suilleabhain PE and Zimmern PE. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000; 56: 250-4.

75. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-34.

76. Seif C, Herzog J, van der Horst C, Schrader B, Volkmann J, Deuschl G et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004; 55: 118-20.

77. Dalmose AL, Bjarkam CR, Sorensen JC, Djurhuus JC and Jorgensen TM. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourol Urodyn 2004; 23: 265-72.

78. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 2006; 129: 3366-75.

79. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. Brain 2008; 131: 132-45.

80. Kessler TM, Burkhard FC, Z'Brun S, Stibal A, Studer UE, Hess CW et al. Effect of thalamic deep brain stimulation on lower urinary tract function. Eur Urol 2008; 53: 607-12.

1. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029-2034.

2. Schiotz HA. One month maximal electrostimulation for genuine stress incontinence in women. Neurourol Urodyn 1994;13:43- 50.

3. Madersbacher H. Intravesical electrical stimulation for the

rehabilitation of the neuropathic bladder. Paraplegia 1990;28:349-352.

4. Merrill DC. The treatment of detrusor incontinence by electrical stimulation. J Urol 1979;122:515-517.

5. Vodusek DB, Light JK, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodyn 1986;5:381-390.

6. Vodusek DB, Plevnik S, Janez J, Vrtacnik P. Detrusor inhibition on selective pudendal nerve stimulation in the perineum. Neurourol Urodyn 1988;6:389-393.

7. Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol 1989;142:340-345.

8. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am 2005;32:11-18. 9. Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Eur Urol 1999;36:81-91.

10. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000;164:1476-1480.

11. Blok BF, Groen J, Bosch JL, Veltman DJ, Lammertsma AA. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 2006;98:1238-1243.

12. Braun PM, Baezner H, Seif C, Boehler G, Bross S, Eschenfelder CC, et al. Alterations of cortical electrical activity in patients with sacral neuromodulator. Eur Urol 2002;41:562- 566; discussion 566-567.

13. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005;174:2268-2272.

14. Kruse MN, de Groat WC. Spinal pathways mediate coordinated bladder/urethral sphincter activity during reflex micturition in decerebrate and spinalized neonatal rats. Neurosci Lett 1993;152:141-144.

15. Zvara P, Sahi S, Hassouna MM. An animal model for the neuromodulation of neurogenic bladder dysfunction. Br J Urol 1998;82:267-271.

16. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007;197:96 e91-95. 17. Bosch RJL, Groen J. Treatment of refractory urge urinary